20
May
2025

Ajinomoto Bio-Pharma Services

Exhibitor at CPHI Americas 2025 stand 720
About Us

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization, with sites in Belgium, United States, Japan, and India, providing comprehensive process development services, cGMP manufacturing and drug product fill finish services of small molecule and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities to rapidly scale from clinical and pilot programs to commercial quantities, including: Corynex technologies, oligonucleotide synthesis, antibody drug conjugations (ADC...

  • US
  • 2018
    On CPHI since
Company types
Manufacturer/Innovator
Contact info
Event information
CPHI Americas 2025
  • 20 May 2025 - 22 May 2025
  • Pennsylvania Convention Center, Philadelphia
  • Visit us at stand 720

Products Featured at CPHI Americas 2025

  • Amino Sciences

    Product Amino Sciences

    The Amino Sciences group in Belgium provides highly pure Ajinomoto Amino Acids for pharmaceuticals, medical food & nutraceuticals, food, and cosmetics & personal care applications to customers in the EMEA.

    Ajinomoto Amino Acids are produced to the highest quality standards under cGMP con...
  • Drug Product Manufacturing

    Product Drug Product Manufacturing

    Ajinomoto Bio-Pharma Services is an established premier CDMO for large, medium, and small molecule APIs offering a unique range of formulation and aseptic filling in vials, prefilled syringes and cartridges to address production needs that span from clinical to commercial phase products. Our global netw...
  • Drug Substance Manufacturing

    Product Drug Substance Manufacturing

    Ajinomoto Bio-Pharma Services offers comprehensive CDMO capabilities for small, medium and large molecule APIs, including high potency, ADCs and oligonucleotides. Our global network provides the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on. That's...